Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filedfiledCritical
Priority to ECSP972082priorityCriticalpatent/ECSP972082A/en
Publication of ECSP972082ApublicationCriticalpatent/ECSP972082A/en
El invento se refiere a composiciones farmacéuticas bien compatible por vía oral, que consta de un núcleo que contiene como sustancia activas derivados de ácidos difosfónicos, el cual está rodeado por una capa de envoltura exenta sustancia activa. Las formas de presentación conformes al invento ponen en libertad la sustancia activa independientemente del valor del pH del medio de liberación.The invention relates to orally compatible pharmaceutical compositions, consisting of a core containing diphosphonic acid derivatives as active substances, which is surrounded by a shell layer free of active substance. The forms of presentation according to the invention release the active substance independently of the pH value of the release medium.
A NEW PHARMACEUTICALLY ACCEPTABLE SALT OF 2-HIDROXI-3- (5- (MORFOLIN-4-ILMETIL) -PIRIDIN-2-L) 1H-INDOL-5-CARBONITRILE, PROCEDURES FOR THE PREPARATION, COMPOSITIONS CONTAINING IT AND APPLICATIONS